A Molecular Docking Study against COVID-19 Protease with a Pomegranate Phyto-Constituents 'Urolithin' and Other Repurposing Drugs: From a Supplement to Ailment

Main Article Content

Varish Ahmad


Aim: We conducted an in silico study on Urolithin and different antimicrobial agents targeting virus protease and peptidase.

Methodology: The docking study was completed by using docking tools. Drug compounds and COVID-19 receptor molecules were prepared, docking was performed and interaction was visualized through Discovery Studio visualizer.

Results: Urolithin A has interacted against peptidase (PDB ID:2GTB) with binding energy -6.93 kcal/mol and against protease (PDB ID:6LU7) with  the binding energy -5.46 kcal/mol, while Urolithin B has interacted to peptidase (PDB ID:2GTB)  with binding energy -6.74 kcal/mol  and with protease it interacted with a binding energy -4.67 kcal/mol. The antimicrobial agent Ofloxacin was found to interact against protease (PDB ID:6LU7) with a binding energy -6.84 kcal/mol and  against protease (PDB:6LU7)  with a binding energy -8.00 kcal/mol.

Conclusion: The most common interacting amino acids of target enzymes of the virus with studied drugs were His41, His164, Met165, Glu166, Gln189. From the docking studies, it is observed that Ofloxacin and Urolithin have the potential to inhibit the virus protease as well as peptidase significantly and these could prevent the entry of the virus to the inside of the host cell. Thus, further antiviral research on these antimicrobial agents and Urolithin could be helpful to control the COVID-19 disease.

Antimicrobial agents, urolithin, antiviral, SARS-CoV-2, protease

Article Details

How to Cite
Ahmad, V. (2020). A Molecular Docking Study against COVID-19 Protease with a Pomegranate Phyto-Constituents ’Urolithin’ and Other Repurposing Drugs: From a Supplement to Ailment. Journal of Pharmaceutical Research International, 32(11), 51-62. https://doi.org/10.9734/jpri/2020/v32i1130545
Original Research Article


Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270–3.

Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. The Lancet 2020;395:470–3.

Coronavirus disease 2019

Available:https://www.who.int/emergencies/ diseases/novel-coronavirus-2019

(Accessed: 2020-04-14)

Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet (London, England) 2020;395:565–74.

Prajapat M, Sarma P, Shekhar N, et al. Drug targets for corona virus: A systematic review. Indian J Pharmacol 2020;52:56–65

Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol. 94.

Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005;309:1864–8.

Dassault Systèmes BIOVIA, [Discovery Studio Visualizer], [Software version 2019], San Diego: Dassault Systèmes; 2019.

Berman HM, Westbrook J, Feng Z, et al. The Protein Data Bank. Nucleic Acids Res. 2000;28(1):235‐242.

DOI: 10.1093/nar/28.1.235.

Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem. 1998;19:1639–62.

Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16): 2785‐2791.

DOI: 10.1002/jcc.21256

Joseph M Blondeau. Fluoroquinolones: Mechanism of Action, Classification, and Development of Resistance. 2004;49 (Suppl 2):S73-8.

Vaishali Chandel, Sibi Raj,Brijesh Rathi,Dhruv Kumar In silico identification of potent FDA approved drugs against Coronavirus. In silico identification of potent FDA approved drugs against Coronavirus COVID-19 main protease: A drug repurposing approach. Chem. Biol. Lett. 2020;7(3):166‐175.

Coskun Usta, Semir Ozdemir, Michele Schiariti, Paolo Emilio Puddu. The pharmacological use of ellagic acid-rich pomegranate fruit, International Journal of Food Sciences and Nutrition. 2013;64(7): 907-913,

DOI: 10.3109/09637486.2013.798268

Faria A, Monteiro R, Mateus N, Azevedo I, Calhau C. Effect of pomegranate (Punica granatum) juice intake on hepatic oxidative stress. Eur J Nutr. 2007;46:271–8.

Shukla M, Gupta K, Rasheed Z, Khan KA, Haqqi TM. Consumption of hydrolysable tannins-rich pomegranate extract suppresses inflammation and joint damage in rheumatoid arthritis. Nutrition. 2008;24: 733–43

TACHOUA Wafa KABRINE Mohamed, Molecular Docking Study of COVID-19 Main Protease with Clinically Approved Drugs. Preprint submitted on 17.05.2020, 18:49 and posted on 19.05.2020.